瑞士Pevion Biotech Ltd www.pevion.com
Pevion生物技術(shù)公司是一家私人擁有的瑞士生物制藥公司，把重點(diǎn)放在發(fā)展預(yù)防性和治療性疫苗的基礎(chǔ)上的市場驗(yàn)證， fluvirus的virosome技術(shù)。 Virosomes小球形囊泡含有病毒膜蛋白（融合蛋白的流感病毒）中嵌入脂膜。它們可裝載幾乎與任何抗原的選擇。 Pevion生物技術(shù)的發(fā)展管道除其他外，包括疫苗候選人對乳腺癌，念珠菌，呼吸道合胞病毒，瘧疾和丙型肝炎病毒。該公司2003年開始作為一家合資公司的巴赫姆控股公司和生物技術(shù)公司的貝爾納，現(xiàn)在Crucell NV公司。
Pevion Biotech is a privately owned Swiss biopharmaceutical company focusing on the development of prophylactic and therapeutic vaccines based on a market-validated, fluvirus-based virosome-technology. Virosomes are small spherical vesicles containing viral membrane proteins (fusion proteins of the influenza virus) embedded in lipid membranes. They can be loaded with almost any antigen of choice. Pevion Biotech’s development pipeline includes, among others, vaccines candidates against breast cancer, Candida, RSV, malaria and HCV. The company started in 2003 as a joint venture company of Bachem Holding AG and of Berna Biotech AG, now Crucell NV. 
 Pevion Biotech successfully applies its proprietary virosome-based technology platforms to the development of efficient and safe prophylactic/therapeutic vaccines. Additionally, Pevion Biotech gives access to these platforms (PeviPROTM and PeviTERTM). Pevion Biotech is located in Bern, Switzerland and has 22 employees.
Pevion Biotech´s high qualified scientists and development personnel are specialized in bringing novel vaccines from research into clinical development.
Pevion Biotech´s virosomes are already market approved and can be manufactured on a large scale under GMP.
Pevion Biotech´s technology can be adapted to meet the various requirements of a state-of-the-art-carrier system.
Pevion Biotech is a partner in vaccine formulation to pharmaceutical companies and research institutions.